The latest price target for Acumen Pharmaceuticals (NASDAQ:ABOS) was reported by HC Wainwright & Co. on November 13, 2024. The analyst firm set a price target for $15.00 expecting ABOS to rise to within 12 months (a possible 525.00% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Acumen Pharmaceuticals (NASDAQ:ABOS) was provided by HC Wainwright & Co., and Acumen Pharmaceuticals reiterated their buy rating.

The last upgrade for Acumen Pharmaceuticals Inc happened on January 21, 2022 when B of A Securities raised their price target to $14. B of A Securities previously had a neutral for Acumen Pharmaceuticals Inc.

There is no last downgrade for Acumen Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acumen Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acumen Pharmaceuticals was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest Acumen Pharmaceuticals (ABOS) rating was a reiterated with a price target of $15.00 to $15.00. The current price Acumen Pharmaceuticals (ABOS) is trading at is $2.40, which is out of the analyst’s predicted range.